晶泰控股(02228)已收到与DoveTree订立的最终协议项下约定的5100万美元的首付款

Group 1 - The core point of the article is that JingTai Holdings (02228) has entered into a final agreement with DoveTree Medicines LLC for drug discovery and development using its AI and robotics platform [1] - The agreement focuses on discovering and developing small molecules and antibody candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders [1] - As part of the agreement, DoveTree will receive exclusive global development and commercialization rights for the products developed [1] - The company has already received an initial payment of $51 million under the terms of the agreement [1]